← Back to Clinical Trials
Recruiting NCT07471373

NCT07471373 Pesticides and Infertility: Oxidative Stress Via Circulating Cell-free DNA and Gut/Genital Microbiome Signatures in Women With Endometriosis

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07471373
Status Recruiting
Phase
Sponsor Centre Hospitalier Universitaire, Amiens
Condition Endometriosis
Study Type INTERVENTIONAL
Enrollment 160 participants
Start Date 2026-02-27
Primary Completion 2028-02

Eligibility & Interventions

Sex Female only
Min Age 18 Years
Max Age 43 Years
Study Type INTERVENTIONAL
Interventions
Circulating DNA analysisVaginal microbiota analysisEndometrial microbiota analysis

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 160 participants in total. It began in 2026-02-27 with a primary completion date of 2028-02.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This project PestiEndoMicro aims to provide an innovative approach, studying endometriosis under the genital and gut microbiota scope. To realize this project, the investigators are planning to dose cfDNA to assess the oxidative stress caused by endometriosis and study its epigenetics. At the same time, the investigators will take a pragmatic approach by assessing pesticide exposure in these patients and estimate the correlation between gut or genital dysbiosis and chemical agent exposure. Also, the investigators will take the initiative to use classic culture, qPCR techniques, and NGS to establish signatures in vaginal, endometrial and gut microbiota in patients with endometriosis. With these approaches, the goal is to gain more knowledge about endometriosis and optimize early diagnosis by establishing a signature in the genital and gut microbiota, but also by dosing the cfDNA. By doing so the investigators could open new opportunities to develop new therapeutic strategies for endometriosis.

Eligibility Criteria

Inclusion Criteria: * The "case" group will include: * All women aged 18 to 43, with confirmed endometriosis and endometriosis grade 3 or 4 as defined by the 1985 revised version of the American Society of Reproductive Medicine. * The "control" group will include: * All women aged between 18 and 43, whose infertility problem is proven male infertility and who do not have endometriosis identified by biological, genetic and clinical tests. * The following criteria will apply to both groups: * All women who have not received antibiotic treatment in the three months preceding inclusion and who are not participating in any pharmacological study. * All women who are covered under the national social security health insurance scheme. * All women who have signed a written informed consent form, thereby confirming their participation in the study after a period of free and informed reflection. Exclusion Criteria: * All women aged 44 and over. * Women who are overweight, obese or anorexic. * Women taking antibiotics 3 months prior to inclusion, or participating in a drug study. * All women under anti-GnRH treatment, pregnant or suffering from a chronic inflammatory disease such as Crohn's disease, polycystic ovary syndrome, etc. * All women whose endometriosis has not been formally confirmed by the tests offered by the Reproductive Medicine and Biology Department, CECOS de Picardie, CHU Amiens-Picardie. * All patients under guardianship, curators or safeguard of justice. * All patients who have not signed the written consent confirming their participation in the study, after a period of free and informed reflection. * Any patient who withdraws her consent for participation in the study.

Contact & Investigator

Central Contact

Moncef BENKHALIFA, Pr

✉ benkhalifa.moncef@chu-amiens.fr

📞 33+3 22 08 73 72

Frequently Asked Questions

Who can join the NCT07471373 clinical trial?

This trial is open to female participants only, aged 18 Years or older, up to 43 Years, studying Endometriosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07471373 currently recruiting?

Yes, NCT07471373 is actively recruiting participants. Contact the research team at benkhalifa.moncef@chu-amiens.fr for enrollment information.

Where is the NCT07471373 trial being conducted?

This trial is being conducted at Salouël, France.

Who is sponsoring the NCT07471373 clinical trial?

NCT07471373 is sponsored by Centre Hospitalier Universitaire, Amiens. The trial plans to enroll 160 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology